View Exam | PowerPak

1. Which of the following statements regarding disease-modifying therapies (DMTs) is CORRECT?

A. Phase III trial data of self-injectable DMTs show a reduction in annual relapse rates of about 60% for all agents. B. Natalizumab, fingolimod, and alemtuzumab are the only DMTs with a REMS. C. Phase III trial data of non-self–injected DMTs show a reduction in annual relapse rates ranging from about 20% to 90%. D. All non-self–injected DMTs are teratogenic in animals, so proof of birth control is required.

2. Lisa is a 54-year-old woman who was diagnosed with relapsing-remitting MS 10 years ago. She started on interferon-β 1b therapy, which she took for 8 years, but then switched to natalizumab 2 years ago because she was tired of injecting herself, the every-other-day dosing, and the flu-like symptoms associated with interferon-β therapy. Lisa works as a receptionist in a real estate office. She is the mother of 3 children; she and her husband divorced 3 years ago. She admits struggling with depression and anxiety over her illness and being a single parent with a long-term illness. She has noticed recent cognitive problems causing forgetfulness and mistakes at work. She is now very concerned about losing her job, wants to give up on her therapy, and feels that life with MS is hopeless and that her medications “don't work.” Which of the following messages to Lisa would be the LEAST helpful way of addressing her adherence issues?

A. Disease-modifying therapies (DMTs) only work if patients take them. B. In clinical studies, DMTs have been shown to reduce relapses and slow disability. C. DMTs will eliminate MS symptoms if they are taken correctly and consistently. D. Adherence issues are common with patients taking DMTs, but studies show that adherence to DMTs is directly correlated with quality of life and being employed.

3. Formulary considerations of risk of progressive multifocal leukoencephalopathy and REMS are applicable to which group of DMTs?

A. B interferons B. Non-self–injected DMTs C. Oral therapies

4. Which of the following is NOT a likely risk of switching DMTs?

A. More severe adverse events B. Breakthrough disease activity C. Loss of insurance coverage D. Rebound disease

5. Which DMT carries a black box warning for fatal autoimmune conditions, life threatening infusion reactions, and increased malignancies?

A. Alemtuzumab B. Fingolimod C. Natalizumab D. Teriflunomide

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding disease-modifying therapies (DMTs) is CORRECT?

3. Formulary considerations of risk of progressive multifocal leukoencephalopathy and REMS are applicable to which group of DMTs?

4. Which of the following is NOT a likely risk of switching DMTs?

5. Which DMT carries a black box warning for fatal autoimmune conditions, life threatening infusion reactions, and increased malignancies?

« Return to Activity

Maintenance is scheduled for 05/16/2024 5:00 PM EST - 05/17/2024 5:00 AM EST.

The shopping cart is empty

Customers who Purchasedthis Activity also Purchased

{{recommendationsA.Title}}

{{recommendationsB.Title}}

1. Which of the following statements regarding disease-modifying therapies (DMTs) is CORRECT?

3. Formulary considerations of risk of progressive multifocal leukoencephalopathy and REMS are applicable to which group of DMTs?

4. Which of the following is NOT a likely risk of switching DMTs?

5. Which DMT carries a black box warning for fatal autoimmune conditions, life threatening infusion reactions, and increased malignancies?

« Return to Activity

Customers who Purchased
this Activity also Purchased